Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Average Price Target of $27.14 According to Analysts

Key Points

• Analysts remain bullish: Eleven firms give Zevra Therapeutics a consensus “Buy” rating, with an average 12-month price target of $27.14 versus the stock’s recent $10.28 opening price.
• Recent results exceeded expectations: Zevra reported quarterly EPS of $0.25, beating the $0.11 consensus estimate, while revenue of $39.66 million surpassed forecasts of $33.88 million.
• Ownership activity is mixed: Company insiders sold shares, while institutional investors—including AIGH Capital Management and Dimensional Fund Advisors—expanded or initiated positions; institutions own 35.03% of the stock.

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus rating of "Buy" from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $27.14.

A number of brokerages recently commented on ZVRA. Guggenheim decreased their price target on Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Friday, August 7th. BTIG Research cut their price target on shares of Zevra Therapeutics from $27.00 to $24.00 and set a "buy" rating on the stock in a report on Monday, July 27th. HC Wainwright reissued a "buy" rating and issued a $26.00 target price on shares of Zevra Therapeutics in a report on Thursday, August 20th. Citizens Jmp boosted their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a "market outperform" rating in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $10.28 on Monday. The firm has a market cap of $610.43 million, a P/E ratio of 11.17 and a beta of 1.01. Zevra Therapeutics has a 52 week low of $8.01 and a 52 week high of $15.03. The firm's 50-day simple moving average is $11.18 and its 200 day simple moving average is $10.74.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. As a group, equities analysts forecast that Zevra Therapeutics will post 0.72 earnings per share for the current year.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director owned 1,800 shares in the company, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil McFarlane sold 20,000 shares of the business's stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $11.25, for a total value of $225,000.00. Following the completion of the sale, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. The trade was a 4.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.70% of the company's stock.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in the business. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the first quarter valued at approximately $11,184,000. Integrity Alliance LLC. bought a new stake in Zevra Therapeutics during the third quarter worth $10,292,000. Dimensional Fund Advisors LP lifted its holdings in Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company's stock valued at $5,168,000 after buying an additional 400,336 shares during the period. Hennion & Walsh Asset Management Inc. grew its position in Zevra Therapeutics by 116.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company's stock worth $5,502,000 after purchasing an additional 206,543 shares in the last quarter. Finally, Mystic Asset Management Inc. grew its position in shares of Zevra Therapeutics by 0.9% during the 3rd quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company's stock valued at $3,899,000 after purchasing an additional 3,270 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra's lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.